An observational study in Type1diabetes, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 2 sites in France. Open to participants aged 12 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies in Diabetes Mellitus, Type 1 with a site in France — 39 open to participants now, 45 under way, 8 of them phase 3. Diabetes Mellitus, Type 1 · France.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, this one is the 35th largest by planned enrollment of the 78 observational ones that give a count, is one of 14 that started in 2022, is one of 78 observational ones, reaches primary completion later than 21 of the 44 other live ones, and was the 200th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →39 of the 271 studies in Diabetes Mellitus, Type 1 with a site in France are open now. Recruiting first, the newest first:
Insulet Corporation · Sites in France
Ages 2+
Sanofi · Sites in France, Belgium, Germany and 3 more countries
Tandem Diabetes Care, Inc. · Sites in France
Ages 6+
Eli Lilly and Company · Sites in France, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in France, United States, Australia and 16 more countries
Ages 1–35
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 12 Months to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 25 · Phase 3 55 · Phase 4 7
First in 2000; this study’s year is marked. 14 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 67 across the 193 interventional studies, 153 across the 78 observational. Of the 205 that completed or were terminated, 48 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
90 of 271 have an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 4 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
17 of the studies in Diabetes Mellitus, Type 1 with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT04583462Phase 3Assistance Publique - Hôpitaux de ParisImpact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes | 2027-09-29 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate in a prospective way changes in Mucosal-Associated Invariant T (MAIT) cells frequency, phenotype and function in link with the gut microbiota, gut integrity and the presence of Coxsackie virus B in two cohorts of pediatric patients: patients with a high genetic risk of type 1 diabetes and pediatric patients with recently diagnosed T1D by comparison with control subjects
Tasks:
Subjects: Multi study. Subjects will be included in the pediatric diabetes and endocrinology unit in Necker Sick children hospital and in the pediatric unit of ANTONY hospital.
Analysis:
MAIT cell analysis: For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression. Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
Gut microbiota analysis: Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
Coxsackie virus B (CVB) infection status: Specific antibodies against coxsackie virus B and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by q-PCR and immunochemistry will be performed on a subset of patients.
Gut integrity: the investigators will assess the permeability of the intestine using the Lactulose-Mannitol test in a sub sample of RO, RD and AR groups (> 5 years of age, n=20). In brief after an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours after ingestion.
Gut mucosa analysis: In a subset of patients (without celiac disease as determined by the dosage of antibodies against transglutaminase), duodenal biopsies will be obtained during an IUG endoscopy . Duodenal biopsy will be performed in RD subjects older than 8 years of age and in CE subjects older than 4 years of age. These biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
Based on previous study, the sample size should allow statistical differences between AR, RO and C groups. The investigators anticipate to observe blood MAIT cell abnormalities in RO patients and some at risk children after seroconversion but before diabetes onset. This new data will strengthen our predictive model (see preliminary data). Since MAIT cells recognize bacterial ligand we hypothesize that MAIT cells alteration could occur in parallel with microbiota changes and/or CVB infection. The investigators anticipate observing gut mucosa abnormalities in RO children and the severity of these abnormalities may correlate with the level of MAIT cells defect and the presence of CVB infection. The investigators expect to demonstrate that MAIT cells represent a new biomarker of progression toward diabetes as well as a functional immune marker of the aggressiveness of the autoimmune disease. As such this study could determine the accurate therapeutic window for preventive strategies based on MAIT cells manipulation.
Study population: patients recently diagnosed with type 1 diabetes and patients with a high risk of type 1 diabetes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Recent onset group
At risk subjects:
Control subjects:
Control subjects for UGI endoscopy:
Exclusion Criteria:
For all groups:
For control subjects for UGI endoscopy control and Recent onset-endoscopy group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with recently diagnosed type 1 diabetes
Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Diagnostic Test: Lactulose/Mannitol Test · Procedure: UGI Endoscopy · Diagnostic Test: Coxsackie virus B infection status
patients with a high genetic risk type 1 diabetes
Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Diagnostic Test: Lactulose/Mannitol Test · Diagnostic Test: Coxsackie virus B infection status
control patients (no risk of type 1 diabetes and no diagnosed type 1 diabetes)
Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Diagnostic Test: Lactulose/Mannitol Test · Diagnostic Test: Coxsackie virus B infection status
patients without type 1 diabetes requiring UGI endoscopy for any medical reason
Diagnostic Test: MAIT cells analysis · Diagnostic Test: MAIT cytokines production analysis · Procedure: UGI Endoscopy · Diagnostic Test: Coxsackie virus B infection status
For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
blood MAIT cells frequency
percentage of MAIT cells in the peripheral blood
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
MAIT cells membrane markers analysis
CD25 positive cells in percentage, CD69 positive cells in percentage, CD44 positive cells in percentage, PD1 positive cells in percentage , KLRG1 positive cells in percentage, TIM3 positive cells in percentage
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
Cytokines production in the cytoplasm of the MAIT
Antibodies against IL- 2 , IFN-y, TNF-α, IL-2, IL-10, IL-13, IL-17 and granzyme B expressed in Cells %
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
MAIT cell ligands measurements
Percentage of MAIT cells activated in vitro when cultivated in presence of subject stool sample
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
Presence of CVB in the stools
CVB specific ARN detection in subjects stools samples by qPCR
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
Blood immunoglobulins against CVB infection statu
Specific antibodies (Ig G) against CVB measurements in patients blood sample
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
Measurement of intestinal gut mucosal permeability
Assessing the permeability of the intestine using the Lactulose-Mannitol test. Concentration of lactulose and manitol in subjects urine samples in mg/dl
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
Evaluation of gut mucosal integrity
qPCR for the expression of key epithelial molecules and cytokines on gut samples
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
16 S sequencing in the Subjects stools
The 16S rRNA gene sequencing will be used for the classification and identification of microbes species in subjects stools. Each species will be identified and quantified as a percentage of the total number of identified species in the stools.
Time frame: Sample collected the day of enrollment (Control group and at risk patients) or up to 7 days after diagnosis and day of enrollment (recent onset group)
Plan to share: No
Started Feb 2022 (actual). Primary completion is estimated for Aug 2027, 66 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 66 months is above that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jan 2022 → Feb 2022 and primary completion Aug 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →